Phreesia Inc (PHR) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Phreesia Inc $6.26, price $9.68, upside -35.3%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Phreesia Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.
Show more
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Stock analysis
Phreesia Inc (PHR) currently trades at $9.68, while our model-based Fair Value estimate is $6.26, implying the stock looks roughly 54.6% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $23.28 per share, and 10 of the 21 models we run sit above the $9.68 price.
Bear case: the Multiples group reads lowest at $0.8200, and 11 of the 21 models stay below the price. Evidence for this calculation is medium.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Phreesia Inc reported revenue of $481M in FY2026 versus $213M in FY2022, a compound +22.5%/yr. Reported net income was $2.3M in FY2026.
Key figures
Market cap $595M · P/E ratio 60.5 · P/S ratio 0.29 · EPS (TTM) $0.1600 · Net margin 0.5% · Return on equity 2.9% · Return on assets (EBIT) −24.8% · Operating margin 5.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 59% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −35%, PHR screens cheaper than that median.
Fair Value models
Bear $6.26Fair Value $6.26Bull $6.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then ($0.1035 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.4%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.3% (2021) → −1.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −4.6% a year for the price and +2.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 135 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−35% · Below median
Profitability
Return on equity (TTM)3% · Above median
Return on assets1% · Above median
Net margin (TTM)2% · Above median
Operating margin (TTM)5% · Above median
Growth and dividend
Revenue growth13% · Above median
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (TTM)60.5× · Priciest 25%
P/B1.77× · Cheaper than median
P/S (TTM)1.20× · Cheaper than median
P/FCF8.8× · Cheaper than median
EV/EBITDA18.6× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)65· sector 34
PAST (return on equity)11· sector 4
HEALTH (low debt)87· sector 98
DIVIDEND (yield)0· sector 46
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Phreesia Inc Fair Value". https://www.fairvalue-calculator.com/stock/PHR
Frequently asked questions
Is Phreesia Inc (PHR) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $6.26 versus a price of $9.68, about −35% upside (overvalued).
What is the fair value of PHR?
Our model-based fair value for Phreesia Inc is $6.26 (as of Sep 23, 2026), built from audited fundamentals. The current price: $9.68.
What is the quality score of PHR?
Phreesia Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phreesia Inc (PHR)?
Our model-based price target is the fair value of $6.26 (as of Sep 23, 2026) from 21 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Phreesia Inc stock forecast for 2026?
Our models put fair value at $6.26, about −35% upside versus a price of $9.68 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Phreesia Inc (PHR)?
Phreesia Inc reported trailing-twelve-month revenue of about $496M (latest available figure, as of Sep 23, 2026).
What growth is priced into Phreesia Inc (PHR)?
For today's price to be fair in a discounted-cash-flow model, Phreesia Inc would have to grow free cash flow by -2.3 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +26.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of PHR use?
Our models discount Phreesia Inc at 10.9 %: a base by market capitalisation (small), damped by beta 0.88, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Phreesia Inc that is -2.3 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Phreesia Inc (PHR) delivered so far?
Over the past 5 years revenue at Phreesia Inc grew +26.5 % a year. The price currently implies -2.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Phreesia Inc (PHR) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Phreesia Inc (-2.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Phreesia Inc (PHR)?
The free-cash-flow yield on the price is 11.38 %: that much free cash flow Phreesia Inc produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Phreesia Inc (PHR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phreesia Inc it is $6.26 per share (as of Sep 23, 2026), against a price of $9.68. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Phreesia Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PHR trades above its calculated fair value: price $9.68, fair value $6.26, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PHR?
No. The price is what the market pays today ($9.68); the fair value is what the company's own numbers justify ($6.26). For Phreesia Inc the two are $3.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Phreesia Inc worth?
The market values Phreesia Inc at about $595M (market capitalisation, as of Sep 23, 2026). Per share that is $9.68; our models calculate a fair value of $6.26 per share.
What is the P/E ratio of PHR?
Phreesia Inc trades at a price-to-earnings ratio of 60.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $6.26 is built from several models across several years. Other multiples: P/B 1.8, P/S 1.2, EV/EBITDA 18.6.
How solid is the balance sheet of Phreesia Inc (PHR)?
Balance-sheet figures for Phreesia Inc (as of Sep 23, 2026): return on equity 2.9%, debt of 0.27 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is PHR from its 52-week high?
Phreesia Inc trades at $9.68, about 59% below its 52-week high of $23.84 and 20% above the low of $8.06 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $6.26 is for.
Which stocks are comparable to Phreesia Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phreesia Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $9.68, calculated fair value $6.26 (−35%), Quality Score 47/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PHR calculated?
We run Phreesia Inc through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Phreesia Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phreesia Inc (PHR)?
The closing price on Sep 23, 2026 was $9.68. Our model-based fair value is $6.26, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phreesia Inc right now?
The price sits above even our optimistic bull case ($6.26). The favourable scenario is already priced in. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Phreesia Inc
How large is the market capitalisation of Phreesia Inc (PHR)?
The market capitalisation of Phreesia Inc is $595M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Phreesia Inc (PHR)?
The price-to-sales ratio of Phreesia Inc is 0.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Phreesia Inc (PHR)?
Earnings per share at Phreesia Inc are $0.1600 (price ÷ EPS = P/E 60.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Phreesia Inc (PHR)?
The net margin of Phreesia Inc is 0.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Phreesia Inc (PHR)?
The return on equity (ROE) of Phreesia Inc is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phreesia Inc (PHR)?
On an EBIT basis the return on assets of Phreesia Inc is −24.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phreesia Inc (PHR)?
The operating margin of Phreesia Inc is 5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phreesia Inc (PHR)?
Revenue at Phreesia Inc is growing +12.9% versus a year earlier (3y avg +19.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Phreesia Inc (PHR) carry?
The net debt of Phreesia Inc is $28.6M (fiscal year 2026, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Phreesia Inc in the live analysis
One click puts Phreesia Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026